Sorafenib With or Without Transarterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma : A Multicenter, Randomized, Controlled Trial

Trial Profile

Sorafenib With or Without Transarterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma : A Multicenter, Randomized, Controlled Trial

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Sorafenib (Primary) ; Doxorubicin; Ethiodized oil
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms SELECT
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Nov 2013 Planned number of patients changed from 362 to 398 as reported by ClinicalTrials.gov.
    • 01 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top